These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 19283860

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immunotoxicity profile of natalizumab.
    Wehner NG, Gasper C, Shopp G, Nelson J, Draper K, Parker S, Clarke J.
    J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
    [Abstract] [Full Text] [Related]

  • 6. Pre- and postnatal development in the cynomolgus monkey following administration of ABT-874, a human anti-IL-12/23p40 monoclonal antibody.
    Enright BP, Tornesi B, Weinbauer GF, Blaich G.
    Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):431-43. PubMed ID: 23212752
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An Enhanced Pre- and Postnatal Development Study in Cynomolgus Monkeys with Tabalumab: A Human IgG4 Monoclonal Antibody.
    Breslin WJ, Hilbish KG, Martin JA, Halstead CA, Newcomb DL, Chellman GJ.
    Birth Defects Res B Dev Reprod Toxicol; 2015 Jun; 104(3):100-16. PubMed ID: 26195230
    [Abstract] [Full Text] [Related]

  • 11. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation.
    Martin PL, Sachs C, Imai N, Tsusaki H, Oneda S, Jiao Q, Treacy G.
    Birth Defects Res B Dev Reprod Toxicol; 2010 Oct; 89(5):351-63. PubMed ID: 20540088
    [Abstract] [Full Text] [Related]

  • 12. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
    Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, Daniels R, Libonati MA, Zanker S, Kugathasan S, International Natalizumab CD305 Trial Group.
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA, Sandrock A.
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, Huemer M, Kunz A, Golaszewski S, Staffen W, Ladurner G, Kraus J.
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008 Jan; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.